Tags

Type your tag names separated by a space and hit enter

Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines from Saudi Parkinson Patients.

Abstract

Background.

Parkinson's disease (PD) is the second most commonly neurodegenerative disease after Alzheimer's disease which occurs to nearly 1% of the population > 50 years old. Inflammatory and bone biomarkers have both become valuable tools for PD diagnosis and prognosis. However, no studies have examined these markers in Saudi patients diagnosed with PD.

Objectives.

To assess the biomarkers and proinflammatory cytokines from blood with PD in serum. Methods. In our study, we included 26 patients with PD and 24 controls. Blood samples were withdrawn from subjects with PD and their matched controls. Biomarkers multiplex assay from Milliplex was used to assess the levels of IL-1B, IL-6, TNF-α, osteoprotegerin (OPG), osteopontin (OPN), and PTH (parathyroid hormone). Data was analyzed using the Statistical Package, GraphPad Prism.

Results.

We found that IL-1β cytokine is significantly higher in patients with PD (p value = 0.0014). However, there are no statistically significant variances found among the two studied groups with regard to the IL-6 and TNF-α cytokines levels. We also found that levels of PTH are decreased in the PD subjects than the age-matched controls (p value= 0.003). Also, the bone matrix glycoproteins, including osteoprotegerin (OPG) and osteopontin (OPN), are significantly upregulated (p value= 0.04 for OPG and p value= 0.003 for OPN), as compared to the controls.

Conclusions.

Our findings are reliable with the possibility that inflammatory and bone markers can be used as biomarkers in PD prognosis. However, to clarify the natural role and consequence of these markers in PD pathology, further larger cohort studies are needed.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King AbdulAziz University, Jeddah, Saudi Arabia.

    ,

    Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

    ,

    National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia.

    National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia.

    Source

    BioMed research international 2019: 2019 pg 2690205

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    31205938

    Citation

    Alrafiah, Aziza, et al. "Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines From Saudi Parkinson Patients." BioMed Research International, vol. 2019, 2019, p. 2690205.
    Alrafiah A, Al-Ofi E, Obaid MT, et al. Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines from Saudi Parkinson Patients. Biomed Res Int. 2019;2019:2690205.
    Alrafiah, A., Al-Ofi, E., Obaid, M. T., & Alsomali, N. (2019). Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines from Saudi Parkinson Patients. BioMed Research International, 2019, p. 2690205. doi:10.1155/2019/2690205.
    Alrafiah A, et al. Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines From Saudi Parkinson Patients. Biomed Res Int. 2019;2019:2690205. PubMed PMID: 31205938.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines from Saudi Parkinson Patients. AU - Alrafiah,Aziza, AU - Al-Ofi,Ebtisam, AU - Obaid,Mona Talib, AU - Alsomali,Nimah, Y1 - 2019/05/08/ PY - 2019/02/27/received PY - 2019/04/15/accepted PY - 2019/6/18/entrez PY - 2019/6/18/pubmed PY - 2019/6/18/medline SP - 2690205 EP - 2690205 JF - BioMed research international JO - Biomed Res Int VL - 2019 N2 - Background. Parkinson's disease (PD) is the second most commonly neurodegenerative disease after Alzheimer's disease which occurs to nearly 1% of the population > 50 years old. Inflammatory and bone biomarkers have both become valuable tools for PD diagnosis and prognosis. However, no studies have examined these markers in Saudi patients diagnosed with PD. Objectives. To assess the biomarkers and proinflammatory cytokines from blood with PD in serum. Methods. In our study, we included 26 patients with PD and 24 controls. Blood samples were withdrawn from subjects with PD and their matched controls. Biomarkers multiplex assay from Milliplex was used to assess the levels of IL-1B, IL-6, TNF-α, osteoprotegerin (OPG), osteopontin (OPN), and PTH (parathyroid hormone). Data was analyzed using the Statistical Package, GraphPad Prism. Results. We found that IL-1β cytokine is significantly higher in patients with PD (p value = 0.0014). However, there are no statistically significant variances found among the two studied groups with regard to the IL-6 and TNF-α cytokines levels. We also found that levels of PTH are decreased in the PD subjects than the age-matched controls (p value= 0.003). Also, the bone matrix glycoproteins, including osteoprotegerin (OPG) and osteopontin (OPN), are significantly upregulated (p value= 0.04 for OPG and p value= 0.003 for OPN), as compared to the controls. Conclusions. Our findings are reliable with the possibility that inflammatory and bone markers can be used as biomarkers in PD prognosis. However, to clarify the natural role and consequence of these markers in PD pathology, further larger cohort studies are needed. SN - 2314-6141 UR - https://www.unboundmedicine.com/medline/citation/31205938/Assessment_of_the_Levels_of_Level_of_Biomarkers_of_Bone_Matrix_Glycoproteins_and_Inflammatory_Cytokines_from_Saudi_Parkinson_Patients L2 - https://dx.doi.org/10.1155/2019/2690205 DB - PRIME DP - Unbound Medicine ER -